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Abstract
Background: Turner Syndrome women are at high risk of vascular disease and the assessment of early risk factors
in Turner Syndrome girls is an emerging focus of research. Our objective was to evaluate endothelial function (EF),
a preclinical measure of atherosclerosis, in Turner Syndrome girls compared with controls.
Methods: A cross-sectional case-control study of Turner Syndrome girls and healthy controls. Subjects underwent
fasting insulin and glucose with calculation of HOMA-IR, fasting lipid profile, anthropometrics, and EF testing using
peripheral arterial tonometry (PAT). Subjects, aged 10-18 years, had karyotype-confirmed Turner Syndrome; growth
hormone (GH), thyroxine and estrogen use were not exclusion criteria. Controls were age- and BMI-matched
healthy girls. Fifteen Turner Syndrome and 15 controls were recruited.
Results: Turner Syndrome girls had lower height, higher HDL and higher waist:height ratio than controls. PAT-
hyperemia ratio (RH-PAT) scores were lower in Turner Syndrome (1.64 ± 0.34 vs. 2.08 ± 0.32, p = 0.002) indicating
impaired EF. Among Turner Syndrome, RH-PAT did not vary with estrogen therapy or with karyotype 45,XO
compared with other karyotypes. However, endothelial function was better in GH-treated compared with GH-
untreated Turner Syndrome (1.80 ± 0.36 vs. 1.4 + 0.22, p = 0.02) although there were no differences in HOMA-IR,
adiponectin or IGF-1.
Conclusion: Girls with Turner Syndrome exhibit impaired endothelial function compared with controls, which may
explain higher risk for vascular disease. GH may protect endothelial function in Turner Syndrome.
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Introduction
Turner Syndrome, a common genetic disorder affecting 1
in 2500 live-born females, is caused by complete or
partial loss of × chromosome [1]. Despite significant
advances in diagnosis and treatment in pediatric settings,
Turner Syndrome patients experience high rates of cardi-
ovascular disease such that adult females with Turner
Syndrome have 3.47 and 2.21 standardized mortality
ratios of coronary and cerebrovascular death respectively
[2]. The majority of this excess mortality risk encom-
passes non-congenital circulatory disease [3]. However,
this relates to underlying congenital structural and
functional arterial abnormalities, which predispose these
patients to aortic dilatation and aneurysm [4]. Addition-
ally, Turner Syndrome patients exhibit a clustering of
acquired cardiovascular disease risk factors, including
increased rates of hypertension, glucose intolerance, obe-
sity and dyslipidemia, which are also impacted by treat-
ment regimens including growth hormone (GH) and
estrogen [1].
Adolescents and young adults rarely experience cardio-
vascular events, and surrogate markers of cardiovascular
disease are needed to evaluate asymptomatic patients.
Impaired endothelial function is an initial step in the
development of atherosclerosis, and represents an early
and reversible step in the vascular disease process [5,6].
The measurement of endothelial function can be used as
a surrogate marker to assess cardiovascular risk [7-10].
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In prior clinical studies, peripheral arterial tonometry
(PAT) testing has been used to measure endothelial func-
tion in both high risk adult [11] and pediatric populations
[12,13]. Assessment of endothelial function has not pre-
viously been reported in pediatric Turner Syndrome
populations and it is unclear whether Turner Syndrome
is an independent risk factor for endothelial damage or if
acquired cardiovascular risk factors impact endothelial
function in this high risk patient group [14,15].
The objectives of this study were to evaluate endothelial
function, as a marker of early vascular disease, in a group
of pediatric Turner Syndrome girls in relation to an age-,
sex- and body mass index (BMI)-matched healthy control
population, and to assess the impact of disease-related
treatment factors and acquired cardiovascular risk factors
on endothelial function in the Turner Syndrome study
group.
Materials and methods
Institutional ethical approval was obtained for this case-
controlled cross-sectional study. Inclusion criteria for
Turner Syndrome subjects included: karyotype-confirmed
diagnosis of Turner Syndrome; patients followed in our
endocrinology clinic; and aged 10-18 years. Individuals
receiving human growth hormone (GH), L-thyroxine or
estrogen, or with a history of congenital heart disease,
were eligible for inclusion. All patients taking L-thyroxine
were on stable therapy with thyroid function within the
normal range. Subjects took their medications as usual on
the day of the study. Controls were healthy girls, age- and
BMI-matched to TS subjects and recruited as part of pre-
vious studies using the same testing protocol. Exclusion
criteria included: inability of the family and/or patient to
comply with study protocol; previous diagnosis of Type 1
or Type 2 Diabetes Mellitus; taking medications for the
treatment of disorders of glucose, insulin or lipid
metabolism.
Each subject attended the Hospital for Sick Children
for full evaluation on two separate days. On one day,
subjects had fasting bloodwork including cholesterol
profile (triglycerides, total cholesterol, high and low den-
sity lipoprotein cholesterol [HDL and LDL]), adiponec-
tin, insulin and glucose. Homeostatic model assessment
of insulin resistance (HOMA-IR) was calculated based
on fasting insulin and glucose values: [16].





)× Insulin (mU/L)] /22.5
Brachial arterial blood pressure (BP) (systolic, diastolic,
and mean) and heart rate were recorded in the left arm
using an automated Dinamap sphygmomanometer (Cri-
tikon Dinamap, Minneapolis, MN, USA). Each subject
underwent history, examination and anthropometrics by
a single examiner. Height, in metres (m), was measured
using a wall-mounted stadiometer; and weight, in kilo-
grams (kg), was assessed using calibrated electronic
scales. BMI was calculated as kg/m2. Pubertal status was
assessed by a single examiner according to the methods
of Tanner [17].
On a different day, subjects returned fasting for
endothelial function testing. PAT (Itamar Medical, Cae-
sarea, Israel) is a non-invasive test which uses pneumatic
probes, similar in shape to a thimble, which cover the fin-
gertip and apply a uniform pressure field which allows for
the measurement of the pulsatile oscillations of the digital
vascular bed microcirculation. The PAT-hyperemia ratio
(RH-PAT) shows a strong sensitivity and specificity for the
detection of coronary endothelial function, which has been
shown to predict cardiovascular events in adult patients
[7,10]. PAT has been used previously as a surrogate mar-
ker of early endothelial function in paediatric populations
[13,18] and, in adolescents it has been validated in a
repeated measures study [19]. PAT probes are placed on
finger II or III of each hand. After a 5 minute equilibration
period, a BP cuff is inflated on the study arm 40 mmHg
above systolic BP for 5 minutes. The cuff is then deflated
and tonometric recording is completed for an additional
5 minutes. The RH-PAT was determined for each patient
and each recording was analyzed individually. Lower RH-
PAT index scores indicate worse endothelial function and
increased risk for atherosclerosis.
Fifteen Turner Syndrome subjects were recruited, and
matched for age and BMI with 15 healthy control girls
(Table 1). All girls and their parents consented to partici-
pate. All subjects completed the protocol. For the girls
with TS, karyotypes were as follows: 45,XO N = 6; 45,
XO/46,XX mosaicism N = 1; 45,XO/47,XXX mosaicism
N = 1; complex translocations N = 3; isochrome q mate-
rial N = 2; 45,XO/46,XY mosaicism N = 2. Two subjects
had aortic stenosis, including one with coarctaction
repair several years previously. One additional subject
had a bicuspid aortic valve. No other TS subjects had any
known cardiovascular disease. Fourteen TS subjects were
taking medications, including: N = 6 estrogen supple-
mentation (N = 1 estrogen only; n = 1 estrogen and pro-
gesterone; N = 1 estrogen, progesterone and GH*; N = 3
oral contraceptive pill) and N = 7 GH supplementation
(N = 4 GH only; N = 1 GH, estrogen and progesterone*;
N = 1 GH and migraine prophylaxis; N = 1 GH with
Ritalin and concerta) and N = 1 calcium supplementation
(* denotes same patient).
Biochemical analyses
Insulin was measured by chemiluminsecence using the
Siemens Immulite 2500 (range of assay 15-2165 pmol/L,
intra-and inter-assay coefficient of variation [CV] <7.6%).
Adiponectin was measured by ELISA (Linco Research
Inc., Range: 1-100 ng/mL; inter-assay CV 2.4 - 8.4%).
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Data analyses
All measures are expressed as mean value ± standard
deviation (SD). Baseline characteristics were compared
with paired t-tests (due to age- and BMI-matching of
patients) and McNemar test. Associations between base-
line characteristics and RH-PAT were quantified with
Pearson Correlation Coefficients. Linear regression was
used to determine whether baseline factors were corre-
lated with outcome measures. All analyses were con-
ducted with SAS, version 9.1 (SAS Institute Inc., Cary,
NC).
Results
There were no statistically significant differences
between the Turner Syndrome and control groups for
age, BP, weight or BMI. Control subjects were signifi-
cantly taller than Turner Syndrome subjects. There was
no difference in waist circumference between the
groups; but, the waist:height ratio was higher in Turner
Syndrome than in controls (Table 1). There were no dif-
ferences between the groups for fasting glucose, LDL,
total cholesterol, or triglycerides. HDL was higher in TS
subjects.
The ages of GH-treated [N = 7] and GH-untreated [N =
8] Turner Syndrome girls were not different (12.7 ± 2.0
years versus 14.3 ± 2.4 years, t = -0.79, p = 0.22) and IGF-
1 levels were not different between GH-treated and GH-
untreated girls (423.8 ± 122.8 versus 336.7 ± 103.6 mcg/L
respectively, p = 0.23). Among the GH-treated Turner
Syndrome girls, GH treatment duration was 4.6 ± 1.1
years, with prescribed GH doses 0.35 mg/kg/week. There
were no statistical differences in HOMA-IR, adiponectin,
lipid measurements or blood glucose between GH-treated
and GH-untreated Turner Syndrome girls (see Table 2).
RH-PAT scores were significantly lower in Turner Syn-
drome than in control subjects (1.64 ± 0.34 versus 2.08 ±
0.32, p = 0.002). Among girls with Turner Syndrome,
RH-PAT scores did not vary with estrogen replacement
therapy (1.56 ± 0.30 with estrogen replacement [N = 6]
versus 1.69 ± 0.37 without estrogen replacement [N = 9],
p = 0.64) or between those with 45,XO karyotype [N = 6]
and other karyotypes [N = 9] (1.60 ± 0.46 versus 1.67 ±
0.26 respectively, p = 0.56). However, RH-PAT scores
were higher in girls receiving GH therapy than in those
not receiving GH therapy (1.86 ± 0.28 versus 1.44 + 0.26
respectively, p = 0.045) and in Turner Syndrome girls
receiving GH therapy, PAT scores were similar to control
girls (1.86 ± 0.28 versus 2.08 ± 0.32 respectively, p =
0.14).
In Turner Syndrome subjects, RH-PAT score did not
correlate with any measures of glucose, adiposity or
anthropometrics. In control subjects, RH-PAT corre-
lated positively with age and systolic BP, and negatively
with LDL and HDL.
Discussion
This study demonstrates that Turner Syndrome girls,
compared with healthy age-, sex- and BMI-matched
controls, have impaired endothelial function, an early,
pre-clinical marker of vascular disease. We did not
observe any significant correlations with acquired CVD
risk factors present in our TS cohort, including lipid
profile, BP or markers of insulin resistance.
The increased risk of cardiovascular complications in
Turner Syndrome patients is complex and encompasses
both congenital and acquired lesions. Recent data from
the UK observed that non-congenital circulatory disease
accounted for 41% of absolute excess mortality in
Table 1 Baseline Demographics and results of investigations and PAT compared between girls with Turner Syndrome
and Control girls
Turner Syndrome N = 15 Control Subjects N = 15 p
Age 13.5 (2.4) 14.3 (1.7) 0.38
Systolic BP (mm Hg) 113.8 (12.2) 106.6 (5.5) 0.06
Diastolic BP (mm Hg) 65.8 (11.5) 70.18 (3.12) 0.21
Height (m) 1.42 (0.11) 1.64 (0.15) 0.0019
Weight (kg) 44.2 (13.0) 54.5 (15.5) 0.07
BMI (kg/m2) 21.5 (4.5) 20.8 (3.4) 0.64
Waist Circumference (cm) 73.1 (10.9) 71.4 (12.8) 0.71
Waist:Height Ratio 0.51 (0.06) 0.44 (0.08) 0.0054
Fasting glucose (mmol/L) 4.55 (0.91) 4.65 (0.47) 0.74
LDL cholesterol (mmol/L) 2.29 (0.58) 2.56 (0.73) 0.29
HDL cholesterol (mmol/L) 1.53 (0.51) 1.00 (0.32) 0.003
Total cholesterol (mmol/L) 4.27 (0.57) 4.08 (0.77) 0.46
Triglycerides (mmol/L) 1.01 (0.48) 0.95 (0.34) 0.71
HDLc:Triglycerides ratio 2.17(1.82) 1.26(0.70) 0.10
RH-PAT 1.64 (0.34) 2.08 (0.32) 0.002
Data are expressed as mean (SD)
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Turner Syndrome women compared with only 8% for
congenital anomalies [3]. Our study describes a young
cohort of reasonably healthy Turner Syndrome patients
with inherent impaired vascular function, of whom only
3/15 have evidence of some cardiac lesion. The Turner
Syndrome patients are compared to BMI-matched
healthy controls, because obesity measures do impair
endothelial function, as we have previously described in
adolescents using the same measure [13]. Previous
reports evaluating vascular function in Turner Syn-
drome have shown carotid intima media thickening pre-
sent in two adult studies, without evidence of abnormal
endothelial function (brachial artery reactivity or pulse
wave velocity) [20,21]. However, these studies were con-
ducted in older Turner Syndrome patients with signifi-
cant differences in BP and BMI compared with healthy
controls.
We identified higher HDL concentrations in Turner
Syndrome subjects compared with controls, and no effect
of GH treatment on any measured cholesterol parameter
was observed. These results are different with respect to
previous studies that have shown higher total cholesterol
in TS subjects independent of age, BMI and karyotype
[22] and higher total cholesterol but lower HDL in older
Turner Syndrome girls compared with controls [23].
Additionally, we identified a tendency towards a
decrease in fasting insulin and HOMA-IR with GH ther-
apy. Previous reports have been mixed. One study identi-
fied increased fasting insulin and glucose in TS girls on
GH therapy [24] and another found no difference in
fasting insulin prior to GH therapy in TS girls compared
with controls, but found increased fasting insulin following
6-12 months of GH therapy [25]. Compared with controls,
in two studies, TS girls on GH therapy had an exaggerated
hyperinsulinaemic response to glucose load [24,26]. The
suggestion of a protective effect of GH on insulin
dynamics and endothelial function in TS girls in this
report indicates that confirmatory studies are required,
using various modalities to assess endothelial function and
glucose-insulin dynamics in TS girls at various ages and
stages of puberty.
We did observe that girls with Turner Syndrome who
were receiving GH therapy had higher RH-PAT scores
than girls with Turner Syndrome who were not receiving
GH therapy, suggesting that GH may offer some endothe-
lial protection in girls with Turner Syndrome. This was
seen in a small number of patients, yet differences in
endothelial function were not noted with estrogen replace-
ment. Using other measures of endothelial or vascular
function, previous studies have identified a protective
effect of GH therapy. Flow-mediated dilatation improves
in GH deficient adults following 3-18 months of GH ther-
apy [27]. GH deficient adolescents had impaired flow-
mediated dilatation, and GH induced a larger increase in
blood flow in GH treated adolescents than in untreated or
healthy controls [28]. Some studies have failed to identify
improvements in vascular function following GH therapy,
including a recent study of endothelial dysfunction in GH
deficient children [29]. Both GH and sex steroids influence
vascular function; GH improves cardiac contractility and
Table 2 Comparison of metabolic parameters between TS subjects GH-treated versus GH-untreated
GH-untreated N = 8 GH-treated N = 7 p-value
Age (years) 14.31(2.38) 12.66(2.00) 0.22
Height (m) 1.43(0.13) 1.40(0.10) 0.95
Weight (kg) 48.01(13.75) 39.79(11.53) 0.17
BMI (kg/m2) 23.02(4.72) 19.82(3.78) 0.24
RH-PAT 1.44(0.26) 1.86(0.28) 0.045
Systolic BP (mm Hg) 113.0(11.56) 114.71(13.70) 0.69
Diastolic BP (mm Hg) 64.88(6.49) 66.86(16.04) 0.65
Waist Circumference (cm) 76.19(11.90) 69.50(9.05) 0.29
Waist:Height Ratio 0.53(0.07) 0.49(0.04) 0.34
HOMA IR 1.90(1.64) 0.68(0.71) 0.06
Adiponectin (ng/mL) 16466(9186) 12995(4466) 0.53
IGF-1 (mcg/L) 423.8(122.8) 336.7(103.6) 0.43
Glucose (mmol/L) 4.79(1.20) 4.29(0.31) 0.95
Insulin (pmol/L) 61.25(44.38) 34.60(20.33) 0.24
HDL (mmol/L) 1.30(0.32) 1.80(0.57) 0.09
LDL (mmol/L) 2.49(0.66) 2.07(0.41) 0.24
Total Cholesterol (mmol/L) 4.27(0.66) 4.27(0.30) 0.78
Triglycerides (mmol/L) 1.14(0.58) 0.89(0.36) 0.33
HDL:Triglycerides Ratio 1.78(1.69) 2.56(2.00) 0.22
Data are expressed as mean(SD)
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vasculature tone [30] while estrogen promotes the release
of nitric oxide thus resulting in vasodilation [31]. There
are various mechanisms by which GH may improve
endothelial function in girls with Turner Syndrome.
Firstly, clinical studies suggest that GH may be beneficial
in non-GH-deficient (non-Turner Syndrome) individuals
with visceral obesity, by reducing abdominal fat and
improving insulin sensitivity [32]. Secondly, studies sug-
gest that the GH-IGF axis is profoundly altered in Turner
Syndrome, specific alterations include a reduction in
bioactive IGF-1 [33]. Finally, in studies of animal models
of GH deficiency, GH treatment has resulted in increased
anti-oxidant capacity and increased resistance to oxidative
stressors [34,35].
Physiologically, inherent differences have been described
as part of the vasculopathy associated with Turner
Syndrome. The precise mechanisms underlying this are
likely multi-factorial and related to endothelial injury;
alterations in Turner Syndrome patients include abnormi-
ties of collagen [36] and impaired release of nitric oxide
[37]. Imbalances in matrix metalloproteinases (MMP)
activity necessary to maintain normal vessel structure has
also been postulated to be present in TS patients [4].
These changes are important in promoting aortic dilation
and aneurysm formation; they also likely act in synergy
with acquired cardiovascular disease risk factors to pro-
mote accelerated atherogenesis in Turner Syndrome.
Several features of this study warrant further comment.
This report is limited by the small number of patients stu-
died and by the absence of significant correlations between
RH-PAT and known traditional cardiovascular risk factors
in the Turner Syndrome cohort. We did not observe any
significant correlations with acquired CVD risk factors
present in our cohort, including abnormal lipid profile,
hypertension or insulin resistance. However, our relatively
small study size and the lack of wide variation in these
variables may account for this finding. We also used his-
torical healthy controls who had undergone previous
endothelial function testing using the same measure and
protocol. While this did allow for matching on the basis of
several confounding variables including age, sex and BMI,
data relating to pubertal status or markers of insulin resis-
tance were not available for comparison in the healthy
control group. Nonetheless, given the nature of Turner
Syndrome, with requirements for pubertal induction, it is
unlikely that groups could be matched simultaneously for
age and pubertal status [38]. Finally, we included 1 Turner
Syndrome girl with a history of CoArctation repair. But
this group of Turner Syndrome girls has not had cardiac
MRI performed and, similar to previous studies [39], it is
therefore possible that MRI would identify additional girls
with structural heart defects. This study confirms that
assessment of endothelial function using the PAT techni-
que is well-tolerated and suitable for use in high risk,
adolescent pediatric cohorts. However, like other tests of
endothelial functionthat serve as surrogate markers of
atherosclerosis, additional longitudinal data are required
to evaluate any predictive value of these measures for
cardiovascular events in adulthood.
Our findings suggest that that Turner Syndrome is an
independent risk factor for impaired endothelial func-
tion at a young age, but GH therapy may be protective
in the Turner Syndrome population. Considering this
inherent vasculopathy, it is important to monitor and
intervene in these patients to reduce the additional bur-
den of acquired cardiovascular disease risk factors
(hypertension, glucose intolerance, obesity and dyslipide-
mia), which are commonly observed in adolescent and
adult Turner Syndrome patients. Regular screening is
essential so that sub-clinical treatable conditions can be
identified, with the ultimate goal of improving morbidity
and mortality.
Conclusions
We identified evidence of impaired endothelial function in
pediatric Turner Syndrome subjects, compared with age-
and BMI-matched female controls. We suggest that pedia-
tricians need to be aware of increased risk of early athero-
sclerosis in pediatric age range Turner Syndrome patients,
and to intervene with diet and lifestyle modifications and
medications as needed. We also suggest that longitudinal
studies are required to follow Turner Syndrome girls
throughout the age spectrum into adulthood to identify
and follow evidence of atherosclerosis.
Figure 1 Impaired endothelial function as shown as lower
mean rh-pat score between subjects with turner syndrome
and controls (mean + sd).
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